Be
Bellus Health (GSK)
Montreal CAFounded 201750 employees
Private CapbiotechAcquiredCNS
Platform: Camlipixant P2X3
Market Cap
N/A
All Drugs
4
Clinical Trials
6
Failed / Terminated
0
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Zanurelsin | BEL-4517 | Preclinical | 2 | KRASG12C | T2D | ||
| BEL-9345 | BEL-9345 | NDA/BLA | 2 | CD38 | WilmsNSCLC | ||
| Pexatinib | BEL-7842 | Phase 3 | 1 | EGFR | MigraineOvarian Ca | ||
| Zanurelsin | BEL-5757 | NDA/BLA | 1 | SMN2 | Pancreatic CaMDD |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (6)